.jpg)
NEW THERAPEUTIC PATHWAY FOR THE TREATMENT OF INFLAMMATORY SKIN DISEASES
EP20820342.2
This invention describe a new alternative therapeutic route for the treatment of inflammatory diseases such as psoriasis or atopic dermatitis. In particular, a new metabolic pathway is proposed for the inhibition of Phartanatos, a form of scheduled cell death involved in inflammatory disease. NAMPT, PARP or AIFM1 protein are used for this inhibition. In addition, certain metabolites, which participate in the metabolic pathway described, allow to offer a prognosis on the predisposition to treatment by light therapy.
Advantages: - Inhibition requires small molecules, easy to synthesis and low cost. - Commercial product for local and non-systemic application.Increased efficiency and lower risks to the patient. - There are candidate molecules in the market, which reduces the times of regulatory processes - Greater customization and effectiveness of light therapy treatment. - Cost reduction for health systems. - Reference research team in your field of knowledge for collaborative development. Applications: - Patent is available for licensing or collaborative development and provides different market opportunities: - Companies with small molecules in their pipeline for PARP or NAMP inhibition, whose goal is focused at inflammatory diseases or other pathologies. - Companies with center of attention in Psoriasis or Atopic Dermatitis therapeutic solutions. - Companies specialized in prediction medical devices.